ArticleACS bio & med chem Au2026
Encapsulation of Exosomal Volatile Organic Compounds for Modulating the NF-κB Pathway in Monocytes.
Article in ACS bio & med chem Au, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cytokines communicate and coordinate immunity, allowing the immune cells to understand one another. Aside from cytokines, a wide variety of molecules modify immune cell behavior and immune responses. We present a study of volatile organic compounds (VOCs) and their capacity to influence the NF-κB signaling pathway in monocytes. By using the U937 monocyte cell line and CRISPR/Cas9 gene editing, we created a model of NFKB1-/- human monocytes. The results showed that exosomes from distinct cells and the same cell have unique VOC signatures when stimulated by LPS. To test the effect of certain VOCs on NF-κB, we encapsulated them in nanoparticles (liposomes). An example is 2-butanone-encapsulated liposomes, which reduced NF-κB and lowered the level of proinflammatory cytokines (TNF-α, IL-8 MCP-1, and IL-1β) in LPS-stimulated monocytes. These results suggest potential therapeutic targets for modulating the NF-κB signaling in monocytes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.